$SKIN

SkinHealth Systems Inc. (SKIN): Results of Operations and Financial Condition

SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-2026q2xearnings.htm EX-99.1 Document Exhibit 99.1 SkinHealth Systems Reports Second Quarter 2026 Financial Results Long Beach, Calif., August 6, 2026 – SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafaci

Original reporting
Published Aug 6, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$SKIN
Neutral
medium confidence
Mentioned
$SKIN
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SKINNeutralMed
01

Why it matters

Traders can update expectations using the revised Q3 and FY 2026 net sales and adjusted EBITDA ranges, and assess whether margin gains offset ongoing sales pressure.

02

Market read

The guidance ranges and the mix of sales decline versus margin/EBITDA improvement are the actionable elements for near-term positioning in SKIN.

03

What to watch

The filing attributes gross margin improvement to prior-year cost effects and notes distributor transitions in Australia/New Zealand and China, which may affect comparability and future sell-through.

Relevance 7/10Novelty 7/10Timing: after-hours filing today, guidance update for Q3 and FY 2026

Background

This is an SEC 8-K (Item 2.02) with Q2 2026 financial results and revised 2026 guidance for SkinHealth Systems, maker of Hydrafacial.

Company-level read

Ticker impact

$SKINNeutralMedium confidence
Context

SkinHealth Systems reported Q2 2026 results and revised 2026 guidance, including Q3 net sales $65-$70M and adjusted EBITDA $5-$7M.

Expected impact

Likely choppy reaction: upside support from higher adjusted EBITDA and gross margin, offset by weaker delivery systems and lower net sales.

Evidence & confidence

The filing discloses both a sales decline and improved gross margin/adjusted EBITDA, plus explicit revised Q3 and FY 2026 ranges that traders can reprice immediately.

Market effects

Provides a read-through for consumer/beauty device and recurring consumables models, highlighting sensitivity to delivery systems demand.

Regional net sales show weakness across Americas, APAC, and EMEA, with distributor transitions noted for Australia/New Zealand and China.

Limited broader market impact; primarily company-specific repricing around guidance and installed-base productivity.

Counterpoint

The adjusted EBITDA outperformance may be partly cost-driven and could fade if delivery systems placements remain weak.

Key entities

  • SkinHealth Systems Inc.

    NASDAQ-listed company reporting Q2 2026 results and revised 2026 guidance.

  • Hydrafacial

    Flagship brand referenced as central to the company’s franchise strategy.

  • Pedro Malha

    CEO quoted on sales pressure, margin improvement, and strategic priorities.

Related articles

$SKINMedAI 8/10

SkinHealth Systems Inc.: SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types

SkinHealth Systems (NASDAQ: SKIN) said the FDA cleared its SkinStylus SteriLock microneedling device to improve periorbital wrinkles in adults 22+ for all Fitzpatrick skin types. The clearance expands indications to include facial acne scars and abdominal hypertrophic scars. The company cited 2025 U.S. microneedling spend of about $330M (+33% YoY) and noted Hydrafacial pairing interest.

$QFINHighAI 8/10

Why is Qfin Holdings stock plummeting today?

Qfin Holdings (QFIN) stock fell 17.6% to $9.50 after reporting Q2 2026 revenue of RMB 3.57B, missing estimates and down 31.6% YoY. Profit dropped to RMB 455M. Analysts downgraded the stock, citing liquidity challenges and weak loan volume. The S&P 500, Dow, and Nasdaq were flat, indicating the decline is company-specific.

$ADIMedAI 8/10

Profits up over three fold at Irish arm of Analog Devices

Analog Devices International UC, the Irish arm of semiconductor manufacturer Analog Devices, reported a 268% increase in pre-tax profits to $1.79 billion for 2025, driven by a 17% revenue rise to $10.02 billion. The company attributed growth to increased demand across all markets and improved gross margins. Dividends paid totaled $4.04 billion, with an additional $200 million declared. The workforce grew by 156 employees, and the company invested in a new facility in Limerick.